News
MacroGenics (MGNX) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET
Operator
Source Fool.com
EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
Why Celldex Therapeutics Blasted 13% Higher on Monday
Clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) was a standout on the stock market Monday. The company's share price closed a sturdy 13% higher on the day, thanks to freshly published
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q3 2023 Earnings CallNov 06, 2023, 8:00 a.m. ET
Operator
Source Fool.com
3 Spectacular High-Yield Dividend Stocks to Buy in November
Not all dividend stocks are in the same league. Some offer puny yields. Others, though, provide exceptionally high ones plus solid long-term growth prospects.
Three Motley Fool contributors think
3 Things About Invitae Every Smart Investor Knows
Genetic-testing company, Invitae (NYSE: NVTA), isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and
1 Under-the-Radar Stock That Could Triple By 2030
Weight-loss medicines are rising in popularity. According to some estimates, this market will be worth $44 billion in risk-adjusted sales by 2030, while it was only valued at $2.5 billion last year
AT&T's 7.5% Dividend Yield Is Looking a Whole Lot Safer Right Now
AT&T (NYSE: T) has long been a solid dividend stock to own. But investors have been losing trust in the stock amid rising interest rates, inflation, and a poor economic outlook. Year to date, it has
Why CRISPR Therapeutics Stock Charged Northward This Week
Gene therapy stocks have been a bright spot in the market this week. For instance, gene correction specialist CRISPR Therapeutics (NASDAQ: CRSP) has so far gained 19.6% through the first four days
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
On Oct. 31, Vertex Pharmaceuticals (NASDAQ: VRTX) and its collaborator CRISPR Therapeutics (NASDAQ: CRSP) met with regulators at the Food and Drug Administration (FDA) in a high-stakes meeting about
Is Novocure Stock a Buy?
Cancer is one of the leading causes of death worldwide. That's why dozens of healthcare companies are constantly seeking new ways to treat, diagnose, or prevent it.
Medical device specialist
Is AbbVie Stock a Buy Now?
With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why now might not seem like a good time to buy AbbVie (NYSE: ABBV) stock. To
Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q3 2023 Earnings CallNov 02, 2023, 4:30 p.m. ET
Operator
Source Fool.com
There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?
It may seem difficult to get excited about Pfizer (NYSE: PFE) these days. After the company brought in record revenue of $100 billion last year thanks to its coronavirus vaccine, Comirnaty, and its
Geron (GERN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q3 2023 Earnings CallNov 02, 2023, 9:00 a.m. ET
Operator
Source Fool.com
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q3 2023 Earnings CallNov 02, 2023, 8:00 a.m. ET
Operator
Source Fool.com
Zoetis (ZTS) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q3 2023 Earnings CallNov 02, 2023, 8:30 a.m. ET
Operator
Source Fool.com
1 Stock Down 15% This Year to Buy and Hold Forever
The past three years have been a roller coaster for Abbott Laboratories (NYSE: ABT). The healthcare giant dealt with a slowdown in its medical device business caused by the pandemic, fluctuating
This High-Yield Dividend Stock Is a Proven Wealth Creator
Found in 1849, Pfizer (NYSE: PFE) has transformed the lives of patients and shareholders alike. The pharmaceutical titan has been one of the best-performing stocks since the end of World War II
Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?
Novavax (NASDAQ: NVAX) is facing some significant headwinds. Its financials aren't in great shape, and its future remains questionable. Investors have been dumping the stock in droves, and it is no
3 Dividend Stocks That Can Power Your Portfolio for Decades
Holding some top dividend stocks in your portfolio can help you generate recurring income for years. This can bolster your savings for retirement or just give you extra money to help pay bills while
EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
The pharmaceutical industry has been a source of extraordinary returns for investors who have picked the right stocks. Since the end of World War II, five of the top 30 performers in the U.S. stock
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
CRISPR Therapeutics (NASDAQ: CRSP) has reached a very important chapter in its growth story. The gene-editing specialist doesn't have products on the market right now, but that could change in just